HRT Prioritizes Access To Affordable Naloxone As US FDA Approves Second OTC Formulation

 
• By Malcolm Spicer
  
RiVive nasal spray is second OTC naloxone formulation approved in US. • Source: Harm Reduction Therapeutics
HBW Podcast

Explore how consumer health is evolving. On the go.

David Ridley hosts in-depth conversations with industry leaders.

SpotifyApple PodcastsWebsite

More from Rx-to-OTC Switch

More from Health